Home Real Estate Drugmaker AbbVie to Buy Cancer Biotech ImmunoGen for $10B
Real Estate

Drugmaker AbbVie to Buy Cancer Biotech ImmunoGen for $10B

North Chicago-based AbbVie will buy ImmunoGen for $10.1 billion in cash, as the drugmaker announced the decision to acquire a maker of promising “guided missile” cancer therapies.ImmunoGen’s Elahere belongs to a new class of treatments called antibody-drug conjugates (ADC) that precisely target cancer cells, potentially reducing toxicity for other cells.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100 percent premium to the company’s recent trading price. The deal centers around Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere brought in $105.2 million in revenue in this year’s third quarter, or nearly all of ImmunoGen’s total sales. AbbVie said the acquisition will speed up its entry into the market for treating solid tumors. 

Source link

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Real Estate

Memphis Dermon Building Converting to 150-Room Hotel

The Dermon Building in Memphis was built 99 years ago, designed as...

Real Estate

Developer Duo Secures $120M Refi for Charleston Harbor Rental Community

Woodfield Investments and Argosy Real Estate Partners have secured $120 million to...

Real Estate

Bonita Springs Site for 252-Unit Apartment Community

Madison Communities and Heitman have closed a $44 million construction loan for...

Real Estate

$21.5M Loan for Tacoma Apartments Secured by Berkadia

Berkadia has secured financing for the acquisition of The Duo Apartments, a...